5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
ADMA Biologics's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 63.40%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ADMA Biologics's 5-Year ROIIC % or its related term are showing as below:
ADMA's 5-Year ROIIC % is ranked better than 80.38% of 1172
companies
in the Biotechnology industry
Industry Median: -10.965
vs ADMA: 63.40
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ADMA Biologics 5-Year ROIIC % Related Terms
ADMA Biologics 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, ADMA Biologics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's 5-Year ROIIC % falls into.
ADMA Biologics's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 153.9967492 (Dec. 2025) - -64.915 (Dec. 2020) )
/
( 477.795 (Dec. 2025) - 132.52 (Dec. 2020) )
=
218.9117492
/
345.275
=
63.40%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ADMA Biologics (ADMA) has a 5-Year ROIIC % of 63.40 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #230 out of 1172 companies in the Biotechnology industry, placing it in the top 19.6%.
Is ADMA Biologics' 5-Year ROIIC % too high?
ADMA Biologics' current 5-Year ROIIC % is 63.40. Based on the distribution chart, ADMA Biologics ranks #230 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' 5-Year ROIIC % compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #230 out of 1172 companies for 5-Year ROIIC %. This places ADMA Biologics in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current 5-Year ROIIC % is 63.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.01, compared to a current price of $8.95 — trading 50.3% below its estimated fair value. The current 5-Year ROIIC % is 63.40. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current 5-Year ROIIC % is 63.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.95 is trading 50.3% below its estimated GF Value™ of $18.01.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
5-Year ROIIC %: 63.40
GF Value™: $18.01 vs. price of $8.95 (50.3% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
